Delivery of drug nanoparticles and methods of use thereof
Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.
1. A method of enhancing penetration of drug nanoparticles into skin, the method comprising applying to the surface of skin a hydrophobic composition comprising greater than 50% w/w of the composition of a continuous hydrophobic carrier comprising petrolatum, 5-24% w/w of the composition of one or more volatile silicone fluids, and 0.1 to 5% w/w of the composition of crystalline taxane nanoparticles,
wherein the mean particle size (number) of the crystalline taxane nanoparticles is from 0.1 microns to 1.5 microns,
wherein the composition does not contain C 1 -C 5 aliphatic alcohols,
wherein the crystalline taxane nanoparticles are capable of penetrating into the epidermal and dermal layers of skin when the composition is applied to the skin,
wherein the composition is a semi-solid ointment, and
wherein the composition does not include an antibiotic and a propellant.
2. The method of claim 1 , wherein the volatile silicone fluid is cyclomethicone.
3. The method of claim 2 , wherein the cyclomethicone is cyclopentasiloxane.
4. The method of claim 1 , wherein the hydrophobic carrier comprises a hydrocarbon.
5. The method of claim 4 , wherein the hydrocarbon is mineral oil, or paraffin wax, or mixtures thereof.
6. The method of claim 1 , wherein the crystalline taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles.
7. The method of claim 6 , wherein the crystalline taxane nanoparticles are paclitaxel nanoparticles.
8. The method of claim 7 , wherein the paclitaxel nanoparticles have a specific surface area (SSA) of at least 18 m 2 /g.
9. The method of claim 1 , wherein the viscosity of the composition is 25,000 cps to 500,000 cps as measured with a Brookfield RV viscometer on a helipath stand with the helipath on, with a T-E spindle at 10 RPM at room temperature for 45 seconds.
10. The method of claim 1 , wherein the hydrophobic composition consists essentially of the continuous hydrophobic carrier, 5-24% w/w of the composition of one or more volatile silicone fluids, and the plurality of crystalline nanoparticles,
wherein the volatile silicone fluid is cyclopentasiloxane,
wherein the continuous hydrophobic carrier is non-volatile and non-polar, greater than 50% w/w of the composition, and consists essentially of petrolatum, heavy mineral oil, and paraffin wax, and
wherein the composition is an anhydrous semi-solid ointment.
11. The method of claim 10 , wherein:
other than cyclopentasiloxane, the hydrophobic composition does not contain an additional skin penetration enhancer nor an additional volatile solvent; and
the hydrophobic composition does not contain a surfactant.
12. The method of claim 10 , wherein the crystalline nanoparticles are paclitaxel nanoparticles, and wherein the composition does not contain a protein or albumin.
13. A hydrophobic composition comprising greater than 50% w/w of the composition of a continuous hydrophobic carrier comprising petrolatum, 5-24% w/w of the composition of one or more volatile silicone fluids, and 0.1 to 5% w/w of the composition of crystalline taxane nanoparticles,
wherein the mean particle size (number) of the crystalline taxane nanoparticles is from 0.1 microns to 1.5 microns,
wherein the composition does not contain C 1 -C 5 aliphatic alcohols,
wherein the crystalline taxane nanoparticles are capable of penetrating into the epidermal and dermal layers of skin when the composition is applied to the skin,
wherein the composition is a semi-solid ointment, and
wherein the composition does not include an antibiotic and a propellant.
14. The composition of claim 13 , wherein the volatile silicone fluid is cyclomethicone.
15. The composition of claim 14 , wherein the cyclomethicone is cyclopentasiloxane.
16. The composition of claim 13 , wherein the hydrophobic carrier comprises a hydrocarbon.
17. The composition of claim 16 , wherein the hydrocarbon is mineral oil, or paraffin wax; or mixtures thereof.
18. The composition of claim 13 , wherein the crystalline taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles.
19. The composition of claim 13 , wherein the crystalline taxane nanoparticles are paclitaxel nanoparticles.
20. The composition of claim 19 , wherein the paclitaxel nanoparticles have a specific surface area (SSA) of at least 18 m 2 /g.
21. The composition of claim 13 , wherein the viscosity of the composition is 25,000 cps to 500,000 cps as measured with a Brookfield RV viscometer on a helipath stand with the helipath on, with a T-E spindle at 10 RPM at room temperature for 45 seconds.
22. The hydrophobic composition of claim 13 consisting essentially of the continuous hydrophobic carrier, 5-24% w/w of the composition of one or more volatile silicone fluids, and the plurality of crystalline taxane nanoparticles, wherein the volatile silicone fluid is cyclopentasiloxane,
wherein the continuous hydrophobic carrier is non-volatile and non-polar, greater than 50% w/w of the composition, and consists essentially of petrolatum, heavy mineral oil, and paraffin wax, and
wherein the composition is an anhydrous semi-solid ointment.
23. The hydrophobic composition of claim 22 , wherein:
other than cyclopentasiloxane, the hydrophobic composition does not contain an additional skin penetration enhancer nor an additional volatile solvent; and
the hydrophobic composition does not contain a surfactant.
24. The composition of claim 22 , wherein the crystalline taxane nanoparticles are paclitaxel nanoparticles, and wherein the composition does not contain a protein or albumin.